JP Morgan Chase’s Ortho Clinical Diagnostics Holdings plc Ordinary Shares OCDX Stock Holding History

JP Morgan Chase’s Portfolio OCDX Stock Details OCDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-8,543,032	Closed	-$159M	–	7195
2022 Q1	$159M	Buy	8,543,032 +1,601,542	+23%	+$28.8M	0.02%	639
2021 Q4	$148M	Buy	6,941,490 +1,352,366	+24%	+$26.6M	0.02%	695
2021 Q3	$103M	Buy	5,589,124 +250,949	+5%	+$5.05M	0.01%	850
2021 Q2	$114M	Buy	5,338,175 +67,109	+1%	+$1.36M	0.01%	838
2021 Q1	$102M	Buy	+5,271,066	New	+$92.9M	0.01%	834

Other funds holding OCDX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

JP Morgan Chase's OCDX Position: Q2 2022 in Review

JP Morgan Chase sold out of Ortho Clinical Diagnostics Holdings plc Ordinary Shares (OCDX) in Q2 2022, closing a stake of 8,543,032 shares — an estimated $159M sold.

JP Morgan Chase first reported a position in OCDX in Q1 2021 and held it in 5 quarters. The position peaked at $159M in Q1 2022. 1 fund tracked by Wall St. Rank holds OCDX as of Q2 2022.

JP Morgan Chase reported no remaining Ortho Clinical Diagnostics Holdings plc Ordinary Shares position as of Q2 2022 after selling out during the quarter.
JP Morgan Chase sold 8,543,032 Ortho Clinical Diagnostics Holdings plc Ordinary Shares shares in Q2 2022, an estimated $159M.
JP Morgan Chase first reported a position in Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q1 2021 and held it in 5 quarters.
JP Morgan Chase's Ortho Clinical Diagnostics Holdings plc Ordinary Shares position peaked at $159M in Q1 2022.
1 fund tracked by Wall St. Rank held Ortho Clinical Diagnostics Holdings plc Ordinary Shares as of Q2 2022.

Based on JP Morgan Chase's 13F filing for Q2 2022, filed 11 Aug 2022.